DR. REDDY'S LABORATORIES LIMITED Dr. Reddy's Laboratories Limited Share Price NSE India S.E.
Equities
DRREDDY
INE089A01023
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,869 INR | -0.67% |
|
-6.75% | +1.22% |
| Sales 2024 | 280B 3.36B 267B | Sales 2025 * | 300B 3.6B 286B | Capitalization | 978B 11.71B 931B |
|---|---|---|---|---|---|
| Net income 2024 | 55.78B 668M 53.1B | Net income 2025 * | 55.44B 664M 52.78B | EV / Sales 2024 | 3.43 x |
| Net cash position 2024 | 64.59B 774M 61.48B | Net cash position 2025 * | 90.85B 1.09B 86.48B | EV / Sales 2025 * | 2.95 x |
| P/E ratio 2024 |
18.4
x | P/E ratio 2025 * |
17.7
x | Employees | 25,863 |
| Yield 2024 |
0.65% | Yield 2025 * |
0.76% | Free-Float | 91.55% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -0.67% | ||
| 1 week | -6.75% | ||
| Current month | -5.41% | ||
| 1 month | -3.53% | ||
| 3 months | -7.36% | ||
| 6 months | +8.28% | ||
| Current year | +1.22% |
1 week
5 818.10
6 114.95
1 month
5 818.106 419.90
Current year
5 520.656 505.90
1 year
4 384.056 505.90
3 years
3 654.006 505.90
5 years
2 351.206 505.90
10 years
1 872.956 505.90
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 01/04/18 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 01/11/20 |
| Chairman | 56 | 17/01/93 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 07/04/86 |
| Chairman | 56 | 17/01/93 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 04/06/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 5,869 | -0.67% | 237 330 |
| 13/05/24 | 5,909 | -0.21% | 170,564 |
| 10/05/24 | 5,921 | +0.74% | 296,180 |
| 09/05/24 | 5,877 | -2.96% | 506,907 |
| 08/05/24 | 6,056 | -3.22% | 988,140 |
Delayed Quote NSE India S.E., May 14, 2024 at 12:49 pm
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
23/07/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
5,871
INR
Average target price
6,100
INR
Spread / Average Target
+3.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.41% | 682B | |
| +30.35% | 586B | |
| -3.78% | 364B | |
| +17.50% | 327B | |
| +3.37% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +7.34% | 165B |
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock
